Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
12,925 JPY | +3.07% | -0.35% | -20.63% |
Apr. 12 | Cosmos Pharmaceutical's Attributable Profit Up 6.6% in Fiscal Nine Months | MT |
Apr. 12 | COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The stock, which is currently worth 2024 to 0.49 times its sales, is clearly overvalued in comparison with peers.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.63% | 3.2B | D+ | ||
-11.45% | 2.97B | D- | ||
+16.31% | 2.81B | - | ||
+11.71% | 2.71B | C+ | ||
-1.34% | 1.91B | - | ||
+9.95% | 1.37B | - | - | |
-22.32% | 941M | - | ||
-39.40% | 716M | - | - | |
-0.53% | 453M | - | D+ | |
+9.65% | 413M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 3349 Stock
- Ratings COSMOS Pharmaceutical Corporation